MALCOLM BRENNER to Time Factors
This is a "connection" page, showing publications MALCOLM BRENNER has written about Time Factors.
Connection Strength
0.215
-
Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia. Clin Cancer Res. 2005 Oct 01; 11(19 Pt 1):6916-23.
Score: 0.029
-
Targeted delivery of adenoviral vectors by cytotoxic T cells. Blood. 2004 Oct 15; 104(8):2272-80.
Score: 0.027
-
Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes. Hum Gene Ther. 2001 Apr 10; 12(6):659-70.
Score: 0.021
-
Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. J Clin Oncol. 2018 04 10; 36(11):1128-1139.
Score: 0.017
-
EBV specific CTL: a model for immune therapy. Vox Sang. 1998; 74 Suppl 2:497-8.
Score: 0.017
-
Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. Blood. 2014 Jun 19; 123(25):3895-905.
Score: 0.013
-
Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol. 2014 Mar 10; 32(8):798-808.
Score: 0.013
-
Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010 Feb 04; 115(5):925-35.
Score: 0.010
-
Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood. 2009 Mar 12; 113(11):2442-50.
Score: 0.009
-
Effects of tumour necrosis factor and alpha interferon on chronic B cell malignancies. Nouv Rev Fr Hematol (1978). 1988; 30(5-6):317-9.
Score: 0.009
-
Recovery of immunoglobulin isotypes following T-cell depleted allogeneic bone marrow transplantation. Br J Haematol. 1986 Sep; 64(1):125-32.
Score: 0.008
-
Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation (RISCT) using antilymphocyte antibodies in patients with high-risk acute myeloid leukemia (AML). Bone Marrow Transplant. 2006 Mar; 37(6):547-52.
Score: 0.008
-
Comparison of the efficiency of transduction of leukemic cells by fiber-modified adenoviruses. Hum Gene Ther. 2004 Dec; 15(12):1229-42.
Score: 0.007
-
Liposomal enhancement of the antitumor activity of conditionally replication-competent adenoviral plasmids. Mol Ther. 2004 Apr; 9(4):489-95.
Score: 0.007
-
Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis. Brain. 2004 May; 127(Pt 5):996-1008.
Score: 0.007
-
CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood. 2000 Feb 15; 95(4):1502-5.
Score: 0.005
-
Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease. Br J Haematol. 1995 Jan; 89(1):98-103.
Score: 0.003
-
Do double-beta-lactam combinations prolong neutropenia in patients undergoing chemotherapy or bone marrow transplantation for hematological disease? Antimicrob Agents Chemother. 1989 Apr; 33(4):503-7.
Score: 0.002
-
Cytotoxic effects of tumour necrosis factor and gamma-interferon on acute myeloid leukaemia blasts. Br J Cancer. 1987 Mar; 55(3):287-90.
Score: 0.002
-
Production of anti-cytomegalovirus antibody following T-cell depleted bone marrow transplant. Br J Haematol. 1986 Aug; 63(4):659-64.
Score: 0.002